EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Migraine in pregnancy: an integrative review

María Karina Vélez-Jiménez, Pablo Schubaroff, Maria Loreto Cid-Jeffs, Ana Mercedes-Robles, Adriana Patricia Martinez-Mayorga, Ildefonso Rodriguez-Leyva, Daniel San-Juan, Javier Andrés Galnares-Olalde, Miguel Angel Morales-Morales, Kevin Espejo-Campos

Headache Medicine · 01.01.2026 · 16 (4) · 209-223

DOI: 10.48208/headachemed.2025.35 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Headache Medicine, online erschienen am 01.01.2026. Verfasst von María Karina Vélez-Jiménez und 9 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BackgroundMigraine is the most prevalent primary headache disorder in pregnancy, with unique clinical implications requiring specialized management approaches.ObjectiveTo provide a comprehensive review of migraine pathophysiology, clinical course, diagnosis, and management during pregnancy, postpartum, and lactation.MethodsSelective literature search of PubMed, Scopus, and Web of Science databases, complemented by AI-assisted tools (Elicit and Consensus) to ensure comprehensive coverage of emerging evidence, from 2003 to 2025.Key FindingsHormonal fluctuations drive migraine pathophysiology, with pregnancy's hormonal stability typically improving symptoms in 60-70% of women with migraine without aura during the second and third trimesters. However, migraine with aura shows less predictable improvement, and de novo attacks may occur. Maternal migraine, particularly with aura, is associated with hypertensive disorders, preterm birth, cesarean delivery, fetal growth restriction, and increased ischemic stroke risk. Psychiatric comorbidities, including depression and anxiety, are frequent and linked to poorer outcomes. Management Non-pharmacological interventions form the foundation of treatment. When pharmacological therapy is required, acetaminophen is first-line, NSAIDs may be used only in the second trimester, and sumatriptan is the safest triptan option. Preventive treatment should be reserved for severe, refractory cases, with magnesium, propranolol, and amitriptyline as evidence-based options.ConclusionMigraine during pregnancy and postpartum requires a multidisciplinary approach prioritizing safe pharmacological strategies, individualized monitoring, and lifestyle optimization to ensure optimal maternal and fetal outcomes.

Zitieren

APA

Vélez-Jiménez, M. K., Schubaroff, P., Cid-Jeffs, M. L., Mercedes-Robles, A., Martinez-Mayorga, A. P., Rodriguez-Leyva, I., San-Juan, D., Galnares-Olalde, J. A., Morales-Morales, M. A., & Espejo-Campos, K. (2026). Migraine in pregnancy: an integrative review. Headache Medicine, 16(4), 209-223. https://doi.org/10.48208/headachemed.2025.35

Vancouver

Vélez-Jiménez MK, Schubaroff P, Cid-Jeffs ML, Mercedes-Robles A, Martinez-Mayorga AP, Rodriguez-Leyva I, et al. Migraine in pregnancy: an integrative review. Headache Medicine. 2026;16(4):209-223. doi:10.48208/headachemed.2025.35

BibTeX
@article{VlezJimnez2026,
  author = {Vélez-Jiménez, María Karina and Schubaroff, Pablo and Cid-Jeffs, Maria Loreto and Mercedes-Robles, Ana and Martinez-Mayorga, Adriana Patricia and Rodriguez-Leyva, Ildefonso and San-Juan, Daniel and Galnares-Olalde, Javier Andrés and Morales-Morales, Miguel Angel and Espejo-Campos, Kevin},
  title = {Migraine in pregnancy: an integrative review},
  journal = {Headache Medicine},
  year = {2026},
  volume = {16},
  number = {4},
  pages = {209--223},
  doi = {10.48208/headachemed.2025.35}
}
Kostenlos starten →